QuidelOrtho beat earnings estimates but saw stock drop 12.8% on Nov. 6, 2025, due to a goodwill charge, lower guidance, and a new FDA test approval.

QuidelOrtho (QDEL) reported third-quarter earnings of $0.80 per share, beating estimates by $0.29, and revenue of $699.9 million, up from last year’s $727.1 million, though down 3.7% year-over-year. Despite the earnings beat, the stock dropped 12.8% on November 6, 2025, due to a large non-cash goodwill impairment charge that caused a GAAP net loss, and a 10.6% reduction in full-year adjusted EPS guidance. The company also received FDA approval for a new diagnostic test. The stock is down 47.9% year-to-date and 50.7% from its 52-week high.